CSL Limited - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360˚ view of the company.

Features:

- Detailed information on CSL Limited required for business and competitor intelligence needs
- A study of the major internal and external factors affecting CSL Limited in the form of a SWOT analysis
- An in-depth view of the business model of CSL Limited including a breakdown and examination of key business segments
- Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for CSL Limited
- Intelligence on CSL Limited’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about CSL Limited, such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends

Highlights:

CSL Limited (CSL or 'the group') is a biopharmaceutical group engaged in the R&D, manufacture, marketing and distribution of biopharmaceutical and allied products. CSL invests in the development of protein-based medicines for treating serious human diseases. The group operates globally through its human health businesses that include the operations of CSL Behring, CSL Bioplasma and CSL Biotherapies. CSL is headquartered in Victoria, Australia and employed about 10,000 people as of June 30, 2011. The group recorded net sales of A$4,187.6 million ($4,141.1 million*) during the financial year ended June 2011 (FY2011), a decrease of 6% compared with FY2010. The operating profit of the group was A$1,212.6 million ($1,199.1 million*) during FY2011, a decrease of 13.2% compared with FY2010. The net profit was A$940.6 million ($930.2 million*) in FY2011, a decrease of 10.7% compared with FY2010. *Calculated using the constant conversion rate of A$1 = $0.9889 for the financial year ended June 30, 2011.

Reasons to Purchase:

- Gain understanding of CSL Limited and the factors that influence its strategies
- Track strategic initiatives of the company and latest corporate news and actions
- Assess CSL Limited as a prospective partner, vendor or supplier
- Support sales activities by understanding your customers' businesses better
- Stay up to date on CSL Limited’s business structure, strategy and prospects